INTRODUCTION
Colorectal cancer (CRC) is one of the most frequent malignancies worldwide, and remains the worldwide leading cause of cancer-related deaths [1, 2] . In Korea, it is the second or third most common cancer and has shown a steep increase in recent decades [3] .
Recently, much attention has been focused on the involvement of cyclooxygenase (COX) in tumor development and progression [4] . COX is a rate-limiting enzyme in the biosynthesis of prostaglandin (PG) from arachidonic acid (AA), and two isoforms have been characterized, COX-1 and COX-2. COX-2 is an inducible enzyme, but it is known to be constitutively overexpressed and to have an oncogenic effect in a variety of cancers, including colorectal cancer.
In addition to COX-2, PG production is also directly dependant on the availability of free AA. AA is released from membrane glycerophospholipids by fatty acid hydrolysis from its sn-2 position by phospholipase A2 (PLA2) and further metabolized by COX to produce PGs and thromboxanes [5] . PLA2 is a key regulatory enzyme in arachidonic acid metabolism, which leads to the synthesis of PGs via COX pathways. There are several types of PLA2 in human cells. Of these, 85 kDa IVA cytosolic PLA2 (cPLA2) has been suggested to be the major intracellular form and thesurgery.or.kr to play an essential role in stimulus induced AA release coupled with COX-2 [6, 7] . Because of this key role of cPLA2 in prostaglandin production it has also been suggested to participate in intestinal tumorigenesis. But the clinical impact of cPLA2 expression on oncologic outcomes in CRC is unclear. In our previous data [8] , we studied the impact of cPLA2, 15-prostaglandin dehydrogenase, and COX-2 expression on tumor progression in CRC and we demonstrated cPLA2 expression was closely associated with COX-2 expression and might have an important role in tumor progression.
Therefore, as a consecutive study, we investigated the survival of patients with CRC to determine the prognostic significance with respect to cPAL2 expression status.
METHODS

Patients and tissue samples
Eighty-eight patients who had undergone surgical resection for primary sporadic colorectal carcinoma by a sin- 
Immunohistochemical staining
Each slide was assessed by a pathologist unaware of patient details. For cPLA2, extent of staining was graded as follows: 0 -staining in less than 1% of tumor cells; 1 -staining in 1 to 20%; 2 -staining in 20 to 50%; and 3 -staining in more than 50%. Overall intensity of staining was also as- sessed as follows: 0 no staining; 1 weak staining; 2 moderate staining; and 3 strong staining. Final scores (range, from 0 to 9) were obtained by multiplying staining extents and intensities. Final scores were described as follows: 0, no expression; 1 to 3, weak expression; 4 to 6, moderate expression; and 7 to 9, strong expression [7] . For statistical analysis, no expression and weak expression were combined and described as negative for expression, and moderate and strong expression were combined and described as positive for expression.
VEGF staining was defined as positive when ＞10% of tumor cells were stained, and as negative when ≤10% of tumor cells were stained [9] . Representative examples of cPLA2 in normal tissue and cancer tissue are shown in Fig.   1 . 
Statistical analysis
RESULTS
Expression of cPLA2 (Table 1) (revised from our previous study [8])
cPLA2 staining was observed in the smooth muscle of the muscularis propria and the muscularis mucosa, in some superficial interstitial cells, and in rare endothelial cells. In normal epithelial cells there was no staining or weak cPLA2 staining (Fig. 1A) . thesurgery.or.kr and disease free survival rates according to cPLA2 expression (Fig. 2) . When we investigated the survival rate of colon and rectal cancer according to cPLA2 expression respectively, no significant difference was shown, statistically.
DISCUSSION
We evaluated the expression profiles of cPLA2 in patients with colorectal cancer in a previous study. Consecutively, in this study, we tried to demonstrate that the expression of cPLA2 had prognostic significance in patients with colorectal cancer.
It has been suggested that colonic tumors release free AA and usually produce more PGs compared with normal mucosa tissue [10] . cPLA2 is a key enzyme for PGs and cPLA2 involvement in intestinal tumorigenesis has been suggested. For the first time, Soydan et al. [11] demonstrated that human colon tumors and associated normal mucosa and submucosa contain high molecular weight cPLA2. Other studies have already reported overexpression of cPLA2 found in 35 to 50% of CRC [7, 12] . We found that cPLA2 was overexpressed in 54.5% of tissue sample tested but cPLA2 expression was not related to other clinicopathologic parameters, except for VEGF expression. VEGF expression showed a statistically significant correlation with cPLA2 expression (P = 0.016).
These results strongly suggest that cPLA2 plays an important role in tumor development and progression in CRC. Similar to our study, it was reported that there was an association between a high number of cPLA2 positive stromal cells and a strong VEGF expression [13] .
cPLA2 expression in animal models has been suggested to be pro-tumourigenic. Homozygous deletion of the cPLA2 gene in mice was found to dramatically reduce small intestinal polyp development but not colonic polyp development, suggesting that cPLA2 had an oncologic effect and a role in tumor promotion [14, 15] . On the other hand, in azoxymethane-induced mouse models, down regulation of cPLA2 attenuated tumor necrosis factor-alpha mediated apoptosis and facilitated tumor progression [16] . Furthermore, knock-out of cPLA2 was found to enhance tumorigenesis in mice, suggesting a proapoptotic role of cPLA2 expression [17] .
As shown in animal models, there are highly variable results on cPLA2 expression in human CRC. Some have suggested that cPLA2 is overexpressed [11] [12] [13] 18] , others, on the other hand, have concluded to the contrary [19] .
Furthermore, in another study, researchers reported that the role of cPLA2 seems not to be the rate-limiting step in PGs formation and cPLA2 plays a minor or no role in human colorectal carcinogenesis [20] .
One previous study showed that acetylsalicylic acid-induced downregulation of cPLA2 expression supports growth inhibition and apoptosis in colon cancer cells [21] .
Panel et al. [7] reported that, in immunohistochemistry of 65 patients with colorectal cancers and Western blot of several colorectal cancer cell lines, cPLA2 was overexpressed in about half of the cases, and that cPLA2 expression was correlated with COX-2 expression, which strongly suggests that cPLA2 plays an important role in tumor development and progression in CRC. But other studies showed that cPLA2 plays an important role in tumor necrosis factor α-induced apoptosis in human colon cancer cells and that colon cancer growth is favored when intracellular AA levels are suppressed by inhibition of cPLA2 [19] .
None of these studies have demonstrated the prognostic effect of cPLA2 expression in patients with CRC.
Regarding patient survival and cPLA2 expression, we found that cPLA2 expression in CRC was not associated with patient survival. This is the first investigation in which survival of patients is evaluated according to cPLA2 expression in CRC. There was only one report in which quantification of group IIA PLA2, not cPLA2, expression seems to provide valuable prognostic information in stage II CRC [22] .
Alterations in the levels and activity of cPLA2 have been associated with cancer pathogenesis in other organs.
cPLA2 expression is increased in several human cancers including small bowel, lung, bile duct and liver [12, [23] [24] [25] .
Proliferation of prostate cancer is also dependant on the thesurgery.or.kr action of cPLA2 [26] .
In conclusion, these results suggest that cPLA2 is constitutively overexpressed and might have an important role in tumor progression. However, cPLA2 expression does not seem to play a role in the prognosis of CRC.
Further large scaled studies are needed to clarify the prognostic effect of cPLA2 in CRC.
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